A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given As a Single Infusion or Dual Infusion Compared With Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy.

Trial Profile

A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given As a Single Infusion or Dual Infusion Compared With Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 May 2017

At a glance

  • Drugs Ocrelizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms FEATURE
  • Sponsors Genentech
  • Most Recent Events

    • 21 May 2010 Status changed from suspended to discontinued.
    • 20 May 2010 According to a Roche/Biogen Idec media release, the ocrelizumab rheumatoid arthritis clinical development programme (including this and the SCRIPT, FILM and STAGE trials) has been discontinued due to an unfavourable overall benefit to risk profile.
    • 08 Mar 2010 Treatment of patients has been suspended after recommendation from the Ocrelizumab RA and Lupus DSMB based on an assessment of this and the SCRIPT, FILM, STAGE, and two lupus trials (BELONG and BEGIN), as reported in a Roche/Biogen Idec media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top